Search for other papers by Seth D. Cohen in
Current site
Google Scholar
PubMed
Search for other papers by Steven Mandel in
Current site
Google Scholar
PubMed
Search for other papers by David B. Samadi in
Current site
Google Scholar
PubMed
Abstract
To properly assess men and women with sexual dysfunction, evaluators should take a biopsychosocial approach that may require consultation with multiple health care professionals from various fields in order to get to the root of the sexual dysfunction; this multidisciplinary methodology offers the best chance of successful treatment. For males, this article focuses on erectile dysfunction (ED) and hypogonadism. The initial evaluation of ED involves a thorough case history, preferably taken from the patient and partner, physical examination, and proper laboratory and diagnostic tests, including an acknowledgment of the subjective complaint. The diagnosis is established on the basis of an individual's report of the consistent inability to attain and maintain an erection sufficient to permit satisfactory sexual intercourse. Initial workups for ED should entail a detailed history that can be obtained from a validated questionnaire such as the International Index of Erectile Function and the Sexual Health Inventory for Men. Hypogonadism is evaluated using the validated Androgen Deficiency in the Aging Male questionnaire and laboratory testing for testosterone deficiency. Treatments logically can begin with the least invasive and then progress to more invasive strategies after appropriate counseling. The last and most important treatment component when caring for men with sexual dysfunction—and, arguably, the least practiced—is close follow-up.
-
1.
Aboseif SR, Wetterauer U, Breza J, et al.The effect of venous incompetence and arterial insufficiency on erectile function: an animal model. J Urol. 1990;144:790–793.
-
2.
Barnett ZL, Robleda-Gomez S, Pachana NA. Viagra: the little blue pill with big repercussions. Aging Ment Health. 2012;16:84–88.
-
3.
Bennett AH, Carpenter AJ, Barada JH. An improved vasoactive drug combination for a pharmacological erection program. J Urol. 1991;146:1564–1565.
-
4.
Bernstein AN, Levinson AW, Hobbs AR, Lavery HJ, Samadi DB. Validation of online administration of the sexual health inventory for men. J Urol. 2013;189:1456–1461.
-
5.
Broderick GA, Arger P. Duplex Doppler ultrasonography: noninvasive assessment of penile anatomy and function. Semin Roentgenol. 1993;28:43–56.
-
6.
Cheitlin MD, Hutter AM Jr, Brindis RG, et al.ACC/AHA expert consensus document. Use of sildenafil (Viagra) in patients with cardiovascular disease. American College of Cardiology/American Heart Association. J Am Coll Cardiol. 1999;33:273–282.
-
7.
Cilurzo P, Canale D, Turchi P, Giorgi PM, Menchini Fabris GF. The RigiScan system in the diagnosis of male sexual impotence. Arch Ital Urol Androl. 1992;64(suppl. 2):81–85.
-
8.
Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Annu Rev Psychol. 2002;53:545–574.
-
9.
Dicks B, Bastuba M, Goldstein I. Penile revascularization—contemporary update. Asian J Androl. 2013;151:5–9.
-
10.
Dorsey P, Keel C, Klavens M, Helstrom WJ. Phosphodiesterase type 5 (PDE5) inhibitors for the treatment of erectile dysfunction. Expert Opin Pharmacother. 2010;11: 1109–1122.
-
11.
Fallon B. Intracavernous injection therapy for male erectile dysfunction. Urol Clin North Am. 1995;22:833–845.
-
12.
Feldman HA, Goldstein I, Hatzichristou DG, Krane RJ, McKinlay J B. Impotence and its medical and psychosocial correlates: results of the Massachusetts Male Aging Study. J Urology. 1994;151:54–61.
-
13.
Floth A, Schramek P. Intracavernous injection of prostaglandin E1 in combination with papaverine: enhanced effectiveness in comparison with papaverine plus phentolamine and prostaglandin E1 alone. J Urol. 1991;145:56–59.
-
14.
Helgason AR, Arver S, Adolfson I, Dickman P, Granath F, Steineck G. “Potency”: the validation of information from a self-administered questionnaire using objective measurements of night-time erections and test-retest reliability. Br J Urol. 1998;81:135–141.
-
15.
Karacan I, Scott FB, Salis PJ, et al.Nocturnal erections, differential diagnosis of impotence, and diabetes. Biol Psychiatry. 1977. Jun;12(3):373–80.
-
16.
Karacan I, Williams RL, Thornby JI, Salis PJ. Sleep related penile tumescence as a function of age. Am J Psychiatry. 1975;132:932–937.
-
17.
Kessler WO. Nocturnal penile tumescence. Urol Clin North Am. 1988 Feb;15(1):81–86.
-
18.
Motiwala HG, Patel DD, Joshi SP, Baxi HM, Desai KD, Shah KN. Experience with penile venous surgery. Urol Int. 1993;51:9–14.
-
19.
Laumann EO, West S, Glasser D, Carson C, Rosen R, Kang J-H. Prevalence and correlates of erectile dysfunction by race and ethnicity among men aged 40 or older in the United States: from the male attitudes regarding sexual health survey. J Sex Med. 22007;4:57–65.
-
20.
Levine AL, Lenting L. Use of nocturnal penile tumescence and rigidity in the evaluation of male erectile dysfunction. Urol Clin North Am. 1995;22:775–788.
-
21.
Licht MR, Lewis RW, Wollan PC, Harris CD. Comparison of RigiScan and sleep laboratory nocturnal penile tumescence in the diagnosis of organic impotence. J Urol. 1995;154:1740–1743.
-
22.
Linet OI, Neff LL. Intracavernous prostaglandin E1 in erectile dysfunction. Clin Investig. 1994;72:139–149.
-
23.
Linet OI, Ogrinc FG. Efficacy and safety of intracavernosal alprostadil in men with erectile dysfunction. The Alprostadil Study Group. N Engl J Med. 1996;334:873–877.
-
24.
Lue TF, Hricak H, Marich KW, Tanagho EA. Vasculogenic impotence evaluated by high-resolution ultrasonography and pulsed Doppler spectrum analysis. Radiology. 1985;155:777–781.
-
25.
Lue TF, Tanagho EA. Physiology of erection and pharmacological management of impotence. J Urol. 1987;137:829–836.
-
26.
Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, et al.Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism. 2000;49:1239–1242
-
27.
Ninan PT. The functional anatomy, neurochemistry, and pharmacology of anxiety. J Clin Psychiatry. 1999;60(suppl 22):12–17.
-
28.
Nutt DJ, Glue P, Lawson C. The neurochemistry of anxiety: an update. Prog Neuropsychopharmacol Biol Psychiatry. 1990;14:737–752.
-
29.
Palmer MJ, Bell AS, Fox DN, Brown DG. Design of second generation phosphodiesterase 5 inhibitors. Curr Top Med Chem. 2007;7:405–419.
-
30.
Porst H, Giuliano F, Glina S, et al.Evaluation of the efficacy and safety of once-a-day dosing of tadalafil 5 mg and 10 mg in the treatment of erectile dysfunction: results of a multicenter, randomized, double-blind, placebo-controlled trial. Eur Urol. 2006;50:351–359.
-
31.
Puyau FA, Lewis RW. Corpus cavernosography. Pressure flow and radiography. Invest Radiol. 1983;18:517–522.
-
32.
Rajkumar RP. The impact of disrupted childhood attachment on the presentation of psychogenic erectile dysfunction: an exploratory study. J Sex Med. 2015 Mar;12(3):798–803
-
33.
Rosen RC, Cappelleri JC, Smith MD, Lipsky J, Pena BM. Development and evaluation of an abridged, 5-item version of the International Index of Erectile Function (IIEF) as a diagnostic tool for erectile dysfunction. Int J Impot Res. 1999;11:319–326.
-
34.
Rosen R, Riley A, Wagner G, et al.The International Index of Erectile Function (IIEF): a multidimensional scale for assessment of erectile dysfunction. Urology. 1997; 49:822–830.
-
35.
Rudnick J, Bödecker R, Weidner W. Significance of the intracavernosal pharmacological injection test, pharmacocavernosography, artificial erection and cavernosometry in the diagnosis of venous leakage. Urol Int. 1991;46:338–343.
-
36.
Shabsigh R, Fishman IJ, Toombs BD, Skolkin M. Venous leaks: anatomical and physiological observations. J Urol. 1991;146:1260–1265.
-
37.
Sachs BD. The false organic-psychogenic distinction and related problems in the classification of erectile dysfunction. Int J Impot Res. 2003;15:72–78.
-
38.
Shamloul R, Ghanem H. Erectile dysfunction. The Lancet. 2013;381:153–165.
-
39.
Sugimori H, Yoshida K, Tanaka T, et al.Relationships between erectile dysfunction, depression, and anxiety in Japanese subjects. J Sex Med. 2005 May;2(3):390–396.
-
40.
Udelson D, Park K, Sadeghi-Nejad H, Salimpour P, Krane RJ, Goldstein I. Axial penile buckling forces vs Rigiscan radial rigidity as a function of intracavernosal pressure: why Rigiscan does not predict functional erections in individual patients. Int J Impot Res. 1999 Dec;11(6):327–337
-
41.
van Ahlen H, Peskar BA, Sticht G, Hertfelder HJ. Pharmacokinetics of vasoactive substances administered into the human corpus cavernosum. J Urol. 1994;151:1227–1230.
-
42.
Wasserman MD, Pollak CP, Spielman AJ, Weitzman ED. The differential diagnosis of impotence. The measurement of nocturnal penile tumescence. JAMA. 1980; 24320:2038–2042.
-
43.
Yang Y, Hu JL, Ma Y, et al.Pharmaco-induced erections for penile color-duplex ultrasound: oral PDE5 inhibitors or intracavernosal injection? Int J Impot Res. 2012;245:191–195.
-
44.
Zimmet P, Alberti KG, Shaw J. Global and societal implications of the diabetes epidemic. Nature 2001;414:782–787.
-
45.
Zorgniotti AW, Lefleur RS. Auto-injection of the corpus cavernosum with a vasoactive drug combination for vasculogenic impotence. J Urol. 1985;133:39–41.
| All Time | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 1034 | 1034 | 76 |
| Full Text Views | 27 | 27 | 0 |
| PDF Downloads | 0 | 0 | 0 |
